

**EFFECT OF METFORMIN TREATMENT ON
ENDOMETRIAL VASCULAR INDICES IN
ANOVULATORY OBESE WOMEN WITH POLYCYSTIC
OVARIAN SYNDROME USING THREE-DIMENSIONAL
POWER DOPPLER ULTRASONOGRAPHY**

THESIS

*Submitted for partial fulfillment of the master degree in Obstetrics and
Gynecology*

By

Samah Aziz Ibrahim

Resident of Obstetrics and Gynecology

Supervised by

Prof. DR. Mostafa Abdel Hamid Seleem

*Professor of Obstetrics and Gynecology
Faculty of Medicine-Cairo University*

Dr. Ahmed Abd El-Magied

*Lecturer of Obstetrics and Gynecology
Faculty of Medicine-Cairo University*

Dr. Reham Zeyada

*Lecturer of Chemical Pathology
Faculty of Medicine-Cairo University*

**Faculty of Medicine
Cairo University**

2015

بسم الله الرحمن الرحيم

"يُؤْتِي الْحِكْمَةَ مَنْ يَشَاءُ وَمَنْ يُؤْتَ
الْحِكْمَةَ فَقَدْ أُوتِيَ خَيْرًا كَثِيرًا وَمَا يَذَّكَّرُ إِلَّا
أُولُو الْأَلْبَابِ"

صدق الله العظيم

سوره البقره: الايه ٢٦٩



Acknowledgement

*It is a great honour to express my deep gratitude and appreciation to **Prof. Dr. Mostafa Abdel Hamid Seleem**, Professor of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, for his encouragement, fatherhood and his guidance throughout the study.*

*I would like to express my sincere thanks and deep gratitude to **Dr. Ahmed Abd Elmageed**, Lecturer of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, for his energetic follow up with constructive advice, criticism and creative suggestions.*

*I am also grateful to **Dr. Reham Zeyada**, Lecturer of Chemical pathology, Faculty of Medicine, Cairo University, for his valuable advice and encouragement throughout the entire study.*

Last, but not least, I would like to thank all members of the Department of Gynecology and Obstetrics, Faculty of Medicine, Cairo University for their help.

Abstract

Introduction: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, affecting 5–10% of women of reproductive age. Its diagnosis is confirmed by the presence of two of the following three disorders: oligomenorrhea or amenorrhea, signs of hyperandrogenism (eg, hirsutism, acne, and alopecia) or elevated levels of total or free testosterone, and polycystic ovaries on sonography. Metformin has been shown to be an effective treatment for anovulatory PCOS patients, not only in terms of menstrual cyclicity but also of fertility. Several randomized controlled trials have shown that PCOS women who resumed ovulation after metformin treatment exhibited a surprisingly high reproductive potential with lower rates of early miscarriage, which may be due to a beneficial action of the drug on endometrial development/receptivity to blastocyst implantation and/or on the quality of the oocytes/embryos.

Objective: The aim of the study is to assess the effect of metformin on the endometrial vascular indices in anovulatory obese PCOS women using three-dimensional power Doppler sonography (3DPDUS).

Method: A prospective study will be set to determine the beneficial effects of metformin on PCOS patients. Total number of participants included in the study 40, will be divided into two groups. Twenty anovulatory obese PCOS patients will be compared with another 20 healthy volunteers who are age- and body mass index-matched).

Results: In the current study, metformin therapy leads to significant increase of endometrial thickness and volume and had no significant effect on uterine RI and PI. On the endometrial level, endometrial and subendometrial VI, FI and VFI increased significantly after metformin treatment.

Conclusion: In summary, short-term administration of metformin in PCOS women resulted in enhancement of the endometrial thickness and volume and endometrial and subendometrial vascular indices on 3DPDUS. This may be one of the possible mechanisms by which metformin improves the reproductive outcome in PCOS patients.

Key words metformin, endometrial vascular indices, power doppler

Contents

	Page
List of Abbreviations	I
List of Tables	IV
List of Figures	V
Introduction	1
Aim of the Work	3
Review of Literature	
• Chapter (1): Polycystic Ovary Syndrome	4
• Chapter (2): Transvaginal Ultrasonography	34
• Chapter (3): Obesity	51
• Chapter (4): Metformin	80
Patients and Methods	88
Results	95
Discussion	104
Summary	116
References	121
Arabic Summary	

List of Abbreviations

17 HP	17 hydroxy progesterone enzyme
21-OH	21 hydroxy progesterone enzyme
2D	Two dimensional
3D	Three dimensional
A4	Androstenedione
ACTH	Adrenocorticotrophin Hormone
AI	Aromatase Inhibitors
ASRM	American Society for Reproductive Medicine
AUC	Area Under Curve
BMI	Body Mass Index
Camp	Cyclic Adenosine Mono-Phosphate
CC	Clomiphene Citrate
DHEA	Dehydroepiandrosterone
DHEAS	Dehydroepiandrosterone Sulfate
DHT	Dihydrotestosterone
DM	Diabetes Mellitus
E1	Estrone
E2	Estradiol
ESHRE	European Society for Human Reproduction and Embryology
FI	Flow Index
FSH	Follicular Stimulating Hormone
GnRH	Gonadotrophin Releasing Hormone
hCG	human Chorionic Gonadotrophin
HDL	High Density Lipoproteins

hMG	human menopausal Gonadotrophins
ICSI	Intra-Cytoplasmic Sperm Injection
IVF	In Vitro fertilization
IVM	In Vitro Maturation
LDL	Low Density lipoprotein
LH	Luteinizing Hormone
LOD	Laparoscopic Ovarian Diathermy
mFG	Modified Ferriman and Gallway score
MG	Mean Grayness
mRNA	Messenger Ribonucleic Acid
NIH	National Institute of Health
OGTT	Oral Glucose tolerance Test
OHSS	Ovarian Hyper stimulation Syndrome
OS	Ovarian Stroma
OV	Ovarian Volume
P4	Progesterone
PCO	Polycystic Ovary
PCOS	Polycystic Ovarian Syndrome
PPCOS	Pregnancy in Polycystic Ovarian Syndrome
RCT	Randomized Controlled Trial
rFSH	recombinant Follicular Stimulating Hormone
SHBG	Sex Hormone Binding Globulin
T	Testosterone
TA	Transabdominal
TSH	Thyroid Stimulating Hormone
TV US	Transvaginal Ultrasound

UER	Ultrasound Examination Route
US	United states
VEGF	Vascular endothelial growth NCAII
	Vascularization flow index
VFI	Vascularization index
VI	Virtual organ computer-aided Analysis
VOCAL	Wan
W	Waist to Hip Ratio
WAIR	

List of Tables

No.	Tilte of table	Page
1	Criteria for defining PCOS	7
2	WHO classification of obesity (WHO, 2005).	54
3	Serum levels of LH and FSH levels between PCOS group and control group.	97
4	Comparison between AGE,BMI between PCOS group and control group.	95
5	Comparison between endometrialvolume, endometrial thickness (as measured by 3 D ultrasound between PCOS group and control group	99
6	Comparison between uterine RI,PI between PCOS group and control group.	100
7	Comparison between endometrial VI, VFI, FI between PCOS group and control group.	102
8	Comparison between SUBENDOMETRIAL VI, VFI, FI between PCOS group and control group.	103

List of Figures

Fig. No.	Title of figure	Page
1	3DPDUS sonograms obtained in a woman with PCOS after treatment day 21 of the cycle with large endometrial volume	48
2	Duplex sonogram obtained on day 14 in a woman with PCOS shows increased resistance in the uterine artery	48
3	The Relationship between Hypothetical BMI-fecundity relationship in PCOS.	55
4	Prevalence of BMI in different age groups in females	56
5	Health Consequences of obesity.	58
6	Typical appearance of an ovary in PCOS	65
7	Evaluation of amenorrhea, anovulation and abnormal bleeding	67
8	Serum levels of LH and FSH levels between PCOS	97
9	Comparison between AGE,BMI between PCOS group and 95 control group	95
10	Comparison between endometrial volume, endometrial thickness (as measured by 3 D ultrasound between PCOS group and control group)	99
11	Comparison between uterine RI, PI between PCOS group and control group	100
12	Comparison between endometrial VI, VFI, FI between PCOS group and control group	102
13	Comparison between SUBENDOMETRIAL VI, VFI, FI between PCOS group and control group	103



INTRODUCTION

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, affecting 5–10% of women of reproductive age. Its diagnosis is confirmed by the presence of two of the following three disorders: oligomenorrhea or amenorrhea, signs of hyperandrogenism (eg, hirsutism, acne, and alopecia) or elevated levels of total or free testosterone, and polycystic ovaries on sonography (US).

PCOS is not only the most common reproductive disorder, but also a plurimetabolic syndrome. Obesity, insulin resistance, and resultant hyperinsulinemia are cardinal features of PCOS with a greater risk of developing diabetes mellitus (DM), hypertension, and dyslipidemia

Recognition of insulin resistance as a principal factor in the pathogenesis of PCOS has led to the use of insulin sensitizers for its treatment. The most extensively studied insulin sensitizer is metformin—an oral antihyperglycemic agent used initially in the treatment of type 2 DM.

Metformin has been shown to be an effective treatment for anovulatory PCOS patients, not only in terms of menstrual cyclicity but also of fertility. Several randomized controlled trials have shown that PCOS women who resumed ovulation after metformin treatment exhibited a surprisingly high reproductive potential with lower rates of early miscarriage which may be due to a beneficial action of the



drug on endometrial development/receptivity to blastocyst implantation and/or on the quality of the oocytes/embryos.

Successful implantation depends on a close dialogue between the blastocyst and the receptive endometrium. Endometrial receptivity can be evaluated by histologic evaluation of an endometrial biopsy, endometrial proteins in uterine flushing, or, more commonly, US examination of the endometrium.

Various US parameters have been used to assess endometrial receptivity including endometrial thickness, pattern, and volume, as well as Doppler study of the uterine arteries and endometrial blood flow. However, Doppler indices may not be representative of the downstream endometrial and subendometrial blood flow. and three-dimensional Doppler US (3DPDUS) may be a more appropriate tool to assess these vascular beds, as it allows reliable and objective assessment through quantification of power Doppler data.



AIM OF THE WORK

This work aimed at evaluating the role of metformin on the endometrial vascular indices in anovulatory obese PCOS women using three-dimensional power Doppler sonography (3DPDUS).

POLYCYSTIC OVARY SYNDROME

(A) Historical Background:

In 1935, Stein and Leventhall first defined a disorder, which would eventually become known as the polycystic ovary (or ovarian) syndrome (PCOS). These gynecologists described 7 women suffering from infertility and amenorrhea and determined, upon surgical exploration, that these women had enlarged ovaries with several superficial cystic structures. Stein and Leventhall performed ovarian wedge resections on these patients, in the belief that they were removing obstructions or cysts from the ovary, which would allow for normal ovarian function to resume. After the surgery, all women resumed their cyclic menses and 5 conceived (**Stein, 1945**).

In 1945, Stein published a follow-up report in which he added excessive male-pattern hair growth and in contrast to what is known today, obesity to the list of symptoms, and noted that the disorder was overall quite rare. The disorder remains a fertile ground for academic debate and research investigation (**Trivax and Azziz, 2007**).

(B) Defining Pcos:

Basics:

PCOS is a functional disorder of unclear etiology, and, as such, is a diagnosis of exclusion, with other androgen excess and ovulatory disorders of clearly defined etiologies excluded. Androgen